LeMaitre Vascular (NASDAQ:LMAT) Issues Quarterly Earnings Results

LeMaitre Vascular (NASDAQ:LMAT) released its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04), FiscalAI reports. LeMaitre Vascular had a return on equity of 15.57% and a net margin of 23.51%. The company had revenue of $67.97 million for the quarter, compared to the consensus estimate of $67.39 million. During the same period last year, the firm earned $0.75 earnings per share. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q3 organic sales grew 12%, driven by 7% pricing and 5% unit growth, with gains across products and regions. LeMaitre reiterated 11% full-year organic growth guidance and expects adjusted EPS to rise 18% to $2.80.
• The B. Braun acquisition adds vascular grafts and other devices with $9.4 million in 2025 sales, but the commercial transition is expected to take 18–24 months. LeMaitre warned of potential customer losses during the transition and expects to record only about $150,000 of related revenue in Q4.
• RestoreFlow revenue grew 34%, including 65% growth in cardiac tissue, but quality-control processing constraints are limiting how much product the company can release and sell. Management said the bottleneck may persist for a while as it adds resources to address it.
• Full-year operating-margin guidance is 27%, with the outlook reduced by about $1.4 million, reflecting the FAS-TIP inventory reserve, faster sales-force and infrastructure investment, RestoreFlow transfer costs, and foreign-exchange pressure. Q3 operating expenses rose 18% year over year.

LeMaitre Vascular Price Performance

NASDAQ LMAT traded down $2.60 during midday trading on Friday, hitting $80.89. The company had a trading volume of 326,441 shares, compared to its average volume of 280,179. The firm has a 50-day moving average price of $81.46 and a 200-day moving average price of $94.14. The company has a market capitalization of $1.85 billion, a PE ratio of 29.41, a P/E/G ratio of 2.54 and a beta of 0.51. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40. LeMaitre Vascular has a twelve month low of $78.22 and a twelve month high of $118.01.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Thursday, November 19th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Thursday, November 19th. This represents a $1.00 annualized dividend and a yield of 1.2%. LeMaitre Vascular’s payout ratio is currently 36.36%.

Wall Street Analyst Weigh In

Several brokerages recently commented on LMAT. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Seaport Research Partners set a $110.00 price target on shares of LeMaitre Vascular in a report on Thursday. Citizens Jmp initiated coverage on shares of LeMaitre Vascular in a report on Thursday. They issued a “market outperform” rating and a $110.00 price target on the stock. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a report on Thursday. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $105.60.

LeMaitre Vascular News Summary

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Citizens JMP initiated coverage with a “Market Outperform” rating and a $110 price target, implying substantial upside from the share price cited in the report. Citizens JMP price target
• Positive Sentiment: Third-quarter revenue rose 11.3% year over year to $67.97 million, topping analysts’ expectations of $67.39 million. The company also declared a $0.25 dividend. Quarterly results Dividend announcement
• Neutral Sentiment: Management plans to participate in three upcoming investor conferences; the announcement did not provide new financial guidance. Investor conferences
• Negative Sentiment: Third-quarter EPS of $0.65 missed the $0.69 consensus and declined from $0.75 a year earlier. Reports also pointed to a cautious outlook, which may outweigh the revenue beat and help explain investor concern. Q3 earnings miss Q3 outlook analysis
• Negative Sentiment: Barrington lowered its price target to $91 from $95, though it maintained an Outperform rating. The reduced target signals less near-term upside in that firm’s view. Barrington price-target change

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.